Who are Levobupivacaine and Fentanyl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bupivacaine-fentanyl elective group, Ropivacaine/Fentanyl, Bupivacaine and Fentanyl, Naropin 0.1% cum sufentanil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levobupivacaine-and-fentanyl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Levobupivacaine and Fentanyl — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Levobupivacaine and Fentanyl (Levobupivacaine and Fentanyl) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic with opioid analgesic combination. Area: Anesthesia and Pain Management.

marketed Local anesthetic with opioid analgesic combination Voltage-gated sodium channels; mu-opioid receptor Anesthesia and Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Levobupivacaine and Fentanyl (Levobupivacaine and Fentanyl) — Hamad Medical Corporation. Levobupivacaine blocks sodium channels to provide local anesthesia, while fentanyl activates opioid receptors to provide analgesia.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Levobupivacaine and Fentanyl TARGET	Levobupivacaine and Fentanyl	Hamad Medical Corporation	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels; mu-opioid receptor
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
Ropivacaine/Fentanyl	Ropivacaine/Fentanyl	National Institute for Tuberculosis and Lung Diseases, Poland	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu opioid receptor (fentanyl)
Bupivacaine and Fentanyl	Bupivacaine and Fentanyl	Bnai Zion Medical Center	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu-opioid receptor (fentanyl)
Naropin 0.1% cum sufentanil	Naropin 0.1% cum sufentanil	Bent Gymoese Jorgensen	phase 3	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu-opioid receptor (sufentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic with opioid analgesic combination class)

Bent Gymoese Jorgensen · 1 drug in this class
Bnai Zion Medical Center · 1 drug in this class
Conrad Arnfinn Bjørshol · 1 drug in this class
Hamad Medical Corporation · 1 drug in this class
National Institute for Tuberculosis and Lung Diseases, Poland · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levobupivacaine and Fentanyl — Competitive Intelligence Brief. https://druglandscape.com/ci/levobupivacaine-and-fentanyl. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab